Articles related to TREATMENTS & PROCEDURES

“A fully oral, inexpensive NMDA-AMPA modulation strategy may offer a practical alternative for patients with the bipolar obsessive-compulsive disorder phenotype who respond poorly to conventional approaches.” — Ngo Cheung, MBBS

“Evenamide has the potential to treat the symptoms of schizophrenia more broadly, addressing also those poorly managed by the currently available antipsychotics.” — Ravi Anand, MD, Therapeutic Advances in Psychopharmacology

“The WOLVERINE meta-analysis provides the strongest evidence to date that MDT improves progression-free survival, radiographic progression-free survival, and castration resistance-free survival.” — Tang et al., The Lancet Oncology

Studies have shown a mean effect size with CBTI of 0.96 compared with 0.87 for pharmacotherapy, suggesting similar efficacy in short term but CBTI seems to have longer-lasting effects.

Treatment preferences shifted to include nonaugmentative antidepressants and electroconvulsive therapy based on changes in patient characteristics.

Silent inactivation (where neutralizing antibodies reduce enzymatic activity without clinical symptoms) can go undetected without therapeutic drug monitoring, leading to subtherapeutic asparagine depletion and increased relapse risk.